Executive Director of Research, In Vivo Therapies Platform
Dr. Xue Zhou has more than 10 years of experience in drug discovery and early clinical development. She joined EdiGene in September 2022.
Prior to EdiGene, Dr. Xue Zhou worked at Retrolead Biopharma, a subsidiary of Hengrui Medicine, and Roche Innovation Center Shanghai, where she led and participated in the discovery, IND submissions, and international multicenter clinical trials of several innovative therapies.
Dr. Xue Zhou holds BS in biochemistry and molecular biology from Peking University. She received her Ph.D. in molecular virology and completed her postdoctoral research at academic medical center, University of Amsterdam, the Netherlands.